TY  - JOUR
AU  - Jovanović, Slobodanka
AU  - Matović, Danijela
AU  - Petrović, Slobodan
PY  - 2011
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/1845
AB  - Intellectual Property Rights (IPRs) and Intangible Assets (IAs) can be highly valuable playing a key role in many fields of business, touching nearly all aspects of a company: products development, human capital, marketing and general management. IP is treated as an asset and a part of the company's portfolio and can be sold, licensed or used for debt finance. Valuation of IP is very important, especially to secure loans or finances for business.
AB  - Prava intelektualne svojine i nematerijalna dobra mogu biti veoma vredna i igrati ključnu ulogu u mnogim oblastima poslovnih aktivnosti i skoro svim aspektima kompanije: razvoja proizvoda, ljudskog kapitala, marketinga, opšteg menadžmenta. Intelektualna svojina se tretira kao dobro i deo portfolia kompanije i može biti prodata, licencirana ili korišćena za finansijske obaveze. Vrednovanje intelektualne svojine je veoma značajno, naročito za obezbeđenje zajmova ili finansiranje poslovnih aktivnosti.
PB  - Economics institute, Belgrade
T2  - Industrija
T1  - Vrednovanje intelektualne svojine
EP  - 117
IS  - 2
SP  - 93
VL  - 39
UR  - https://hdl.handle.net/21.15107/rcub_technorep_1845
ER  - 

@article{
author = "Jovanović, Slobodanka and Matović, Danijela and Petrović, Slobodan",
year = "2011",
abstract = "Intellectual Property Rights (IPRs) and Intangible Assets (IAs) can be highly valuable playing a key role in many fields of business, touching nearly all aspects of a company: products development, human capital, marketing and general management. IP is treated as an asset and a part of the company's portfolio and can be sold, licensed or used for debt finance. Valuation of IP is very important, especially to secure loans or finances for business., Prava intelektualne svojine i nematerijalna dobra mogu biti veoma vredna i igrati ključnu ulogu u mnogim oblastima poslovnih aktivnosti i skoro svim aspektima kompanije: razvoja proizvoda, ljudskog kapitala, marketinga, opšteg menadžmenta. Intelektualna svojina se tretira kao dobro i deo portfolia kompanije i može biti prodata, licencirana ili korišćena za finansijske obaveze. Vrednovanje intelektualne svojine je veoma značajno, naročito za obezbeđenje zajmova ili finansiranje poslovnih aktivnosti.",
publisher = "Economics institute, Belgrade",
journal = "Industrija",
title = "Vrednovanje intelektualne svojine",
pages = "117-93",
number = "2",
volume = "39",
url = "https://hdl.handle.net/21.15107/rcub_technorep_1845"
}

Jovanović, S., Matović, D.,& Petrović, S.. (2011). Vrednovanje intelektualne svojine. in Industrija
Economics institute, Belgrade., 39(2), 93-117.
https://hdl.handle.net/21.15107/rcub_technorep_1845

Jovanović S, Matović D, Petrović S. Vrednovanje intelektualne svojine. in Industrija. 2011;39(2):93-117.
https://hdl.handle.net/21.15107/rcub_technorep_1845 .

Jovanović, Slobodanka, Matović, Danijela, Petrović, Slobodan, "Vrednovanje intelektualne svojine" in Industrija, 39, no. 2 (2011):93-117,
https://hdl.handle.net/21.15107/rcub_technorep_1845 .

TY  - JOUR
AU  - Jovanović, Slobodanka
AU  - Matović, Danijela
AU  - Petrović, Slobodan
PY  - 2010
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/1580
AB  - The pharmaceutical industry consists of two sectors: the innovative sector and generic sector. The innovative pharmaceutical industry is totally dependent on patents and these companies are focused on protecting against commodity and branded generics. Global pharmaceutical markets have experienced dramatic changes in recent years. The current global financial crisis is likely to hit pharmaceutical companies due to a lack of funding for research and production of many new drugs , while the national governments, concerned with the rising cost of pharmaceuticals within their national healthcare budgets, are striving to promote the use of generics over high-priced originator products. Serbia has the innovative generic pharmaceutical industry. .
AB  - Farmaceutsku industriju sačinjavaju dva sektora: inovativni i generički sektor. Inovativna farmaceutska industrija je u potpunosti zavisna od patenata i ove kompanije su fokusirane na zaštitu od generika (zaštićenih ili nezaštićenih žigom). Svetsko farmaceutsko tržište je pretrpelo dramatične promene poslednjih godina. Tekuća svetska finansijska kriza je izgleda pogodila farmaceutske kompanije zbog nedostatka fondova za istraživanje i proizvodnju mnogih novih lekova, dok nacionalne vlade obzirom na povećanje troškova lekova u okviru nacionalnog zdravstvenog budžeta, nastoje da promovišu generike u odnosu na skuplje originalne proizvode. Srbija ima inovativno - generičku industriju.
PB  - Economics institute, Belgrade
T2  - Industrija
T1  - Innovative and generic pharmaceuticals industry and drugs market
T1  - Inovativna i generička farmaceutska industrija i tržište lekova
EP  - 119
IS  - 1
SP  - 105
VL  - 38
UR  - https://hdl.handle.net/21.15107/rcub_technorep_1580
ER  - 

@article{
author = "Jovanović, Slobodanka and Matović, Danijela and Petrović, Slobodan",
year = "2010",
abstract = "The pharmaceutical industry consists of two sectors: the innovative sector and generic sector. The innovative pharmaceutical industry is totally dependent on patents and these companies are focused on protecting against commodity and branded generics. Global pharmaceutical markets have experienced dramatic changes in recent years. The current global financial crisis is likely to hit pharmaceutical companies due to a lack of funding for research and production of many new drugs , while the national governments, concerned with the rising cost of pharmaceuticals within their national healthcare budgets, are striving to promote the use of generics over high-priced originator products. Serbia has the innovative generic pharmaceutical industry. ., Farmaceutsku industriju sačinjavaju dva sektora: inovativni i generički sektor. Inovativna farmaceutska industrija je u potpunosti zavisna od patenata i ove kompanije su fokusirane na zaštitu od generika (zaštićenih ili nezaštićenih žigom). Svetsko farmaceutsko tržište je pretrpelo dramatične promene poslednjih godina. Tekuća svetska finansijska kriza je izgleda pogodila farmaceutske kompanije zbog nedostatka fondova za istraživanje i proizvodnju mnogih novih lekova, dok nacionalne vlade obzirom na povećanje troškova lekova u okviru nacionalnog zdravstvenog budžeta, nastoje da promovišu generike u odnosu na skuplje originalne proizvode. Srbija ima inovativno - generičku industriju.",
publisher = "Economics institute, Belgrade",
journal = "Industrija",
title = "Innovative and generic pharmaceuticals industry and drugs market, Inovativna i generička farmaceutska industrija i tržište lekova",
pages = "119-105",
number = "1",
volume = "38",
url = "https://hdl.handle.net/21.15107/rcub_technorep_1580"
}

Jovanović, S., Matović, D.,& Petrović, S.. (2010). Innovative and generic pharmaceuticals industry and drugs market. in Industrija
Economics institute, Belgrade., 38(1), 105-119.
https://hdl.handle.net/21.15107/rcub_technorep_1580

Jovanović S, Matović D, Petrović S. Innovative and generic pharmaceuticals industry and drugs market. in Industrija. 2010;38(1):105-119.
https://hdl.handle.net/21.15107/rcub_technorep_1580 .

Jovanović, Slobodanka, Matović, Danijela, Petrović, Slobodan, "Innovative and generic pharmaceuticals industry and drugs market" in Industrija, 38, no. 1 (2010):105-119,
https://hdl.handle.net/21.15107/rcub_technorep_1580 .